These findings highlight the potential role of PPAR subtypes (particularly PPARγ) and their ligands with anti-inflammatory effects during the COVID-19 pandemic, which can be promising candidates for inhibiting key inflammatory factors (especially NF-κB and AP-1), thus regulating inflammation during SARS-CoV-2 infection. Here, NFKB1 is linked to COVID-19.